aTYR PHARMA INC (ATYR) stock
ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.08−0.91 (-18.24%)
Close on Nov 18, 2026Market cap $400.20MP/E –Yield –
aTYR PHARMA revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
aTYR PHARMA's revenue for the twelve months ending Dec 31, 2025 was $190.00K, down 19.1% year over year. For fiscal 2025 it was $190.00K, down 19.1% from the year before. The highest annual figure on record is $10.46M in fiscal 2020.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $190.00K | -19.1% |
| FY2024 | Dec 31, 2024 | $235.00K | -33.4% |
| FY2023 | Dec 31, 2023 | $353.00K | -96.6% |
| FY2022 | Dec 31, 2022 | $10.39M | – |
| FY2021 | Dec 31, 2021 | $0 | -100.0% |
| FY2020 | Dec 31, 2020 | $10.46M | +2377.5% |
| FY2019 | Dec 31, 2019 | $422.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $0 | – |
| Q3 FY2025 | Sep 30, 2025 | $190.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
| Q1 FY2025 | Mar 31, 2025 | $0 | -100.0% |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $0 | – |
| Q1 FY2024 | Mar 31, 2024 | $235.00K | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $353.00K | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | -100.0% |
| Q1 FY2023 | Mar 31, 2023 | $0 | -100.0% |
| Q4 FY2022 | Dec 31, 2022 | $10.39M | +5395.2% |
| Q3 FY2022 | Sep 30, 2022 | $0 | -100.0% |
| Q4 FY2020 | Dec 31, 2020 | $2.05M | +1325.7% |
| Q3 FY2020 | Sep 30, 2020 | $148.00K | -19.6% |
| Q2 FY2020 | Jun 30, 2020 | $189.00K | +101.1% |
| Q1 FY2020 | Mar 31, 2020 | $8.07M | – |
| Q4 FY2019 | Dec 31, 2019 | $144.00K | – |
| Q3 FY2019 | Sep 30, 2019 | $184.00K | – |
| Q2 FY2019 | Jun 30, 2019 | $94.00K | – |
See a number that looks wrong?